XNAS
RNAC
Market cap196mUSD
Oct 08, Last price
6.82USD
1D
2.10%
1Q
-27.91%
Jan 2017
-98.67%
IPO
-98.38%
Name
Selecta Biosciences Inc
Chart & performance
P/E
—
P/S
71.64
EPS
—
Div yield, %
—
Shrs. gr., 5y
56.00%
Rev. gr., 5y
-29.96%
Revenues
3m
-92.81%
Net income
-130m
L+68.30%
CFO
-74m
L+212.33%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Key people
Carsten Brunn
President, Chief Executive Officer, Director · since 2018
Chief Financial Officer · since 2022
Emily English
Senior Vice President, Head of Manufacturing Operations · since 2024
Chris Jewell
Chief Scientific Officer · since 2023
Milos Miljkovic
Chief Medical Officer · since 2023
Patrick Zenner
Lead Independent Director · since 2025
Adrian Bot
Director · since 2025
Director · since 2024
Timothy Barabe
Independent Director · since 2016
Independent Chairman of the Board · since 2019
Nishan de Silva
Independent Director · since 2021
Murat Kalayoglu
Independent Director · since 2023
Independent Director · since 2023
Independent Director · since 2018
IPO date
Jun 22, 2016
Employees
64
Domiciled in
US
Incorporated in
US
Legal address
c/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St
Wilmington, DE 19801
US
Wilmington, DE 19801
US
Headquarters
480 Arsenal Way
Watertown, MA 02472
US
Watertown, MA 02472
US
Previous name
Selecta Biosciences, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||